* BCR-ABL tyrosine kinase inhibitors (TKIs) are effective against chronic myeloid leukemia (CML), but they rarely eliminate CML stem cells. Disease relapse is common upon therapy cessation, even in patients with complete molecular responses. Furthermore, once CML progresses to blast crisis (BC), treatment outcomes are dismal. We hypothesized that concomitant targeting of BCL-2 and BCR-ABL tyrosine kinase could overcome these limitations. We demonstrate increased BCL-2 expression at the protein level in bone marrow cells, particularly in Lin , and quiescent stem/progenitor CD34 + cells from BC CML patient samples. Our results suggest that BCL-2 is a key survival factor for CML stem/progenitor cells and that combined inhibition of BCL-2 and BCR-ABL tyrosine kinase has the potential to significantly improve depth of response and cure rates of chronic-phase and BC CML.
INTRODUCTION
Chronic myeloid leukemia (CML) is characterized by the t(9;22) Philadelphia translocation in hematopoietic stem cells, which results in constitutive activation of BCR-ABL tyrosine kinase and aberrant myeloid cell proliferation. BCR-ABL tyrosine kinase inhibitors (TKIs) are the most successful class of molecular targeted therapy of any malignant disease, and as such, they are the first-line therapy for newly diagnosed CML. However, they are inactive against CML stem cells (1-3). Hence, cures of CML with TKIs are rare (4) .
CML stem cells are quiescent, and this likely accounts for the lack of disease eradication by TKIs in most patients (1) (2) (3) (4) (5) (6) (7) (8) . CML stem cells can accumulate additional mutations, including those in BCR-ABL, and thus may provide a reservoir for the emergence of drug-resistant clones. With additional mutations, activation of alternative signaling pathways, and mechanisms that are not fully understood, a subset of CML progresses to blast crisis (BC). Not surprisingly, TKIs are essentially ineffective against BC CML (9) , and treatment options for these patients are limited. Furthermore, in these patients, leukemia stem cells can also originate from progenitor cells that acquire self-renewal capacity (10) . Therefore, strategies that eradicate CML stem cells and target BC CML are needed to improve true cure rates in chronic-phase CML and treatment outcomes in BC CML.
BCL-2 family proteins are key regulators of mitochondrial-mediated apoptosis (11, 12) and critical for the survival of leukemia and leukemia stem cells (13) (14) (15) (16) . BCL-2 antiapoptotic protein expression is higher in CML than in normal hematopoietic stem cells and is further increased in BC CML (17, 18) . BCR-ABL signaling supports CML cell survival, in part, by up-regulating antiapoptotic BCL-2 proteins including BCL-X L and MCL-1 (19, 20) . We and others have reported that combined treatments with dual BCL-2/BCL-X L or pan-BCL-2 inhibitors and TKIs can eliminate CML stem/progenitor cells (17, (21) (22) (23) . Recently, we demonstrated that activation of p53 in combination with BCL-2/BCL-X L or BCR-ABL inhibition has synergistic effects in CD34 + proliferating and quiescent BC CML cells, in part, by inducing proapoptotic and suppressing antiapoptotic BCL-2 proteins (24) . However, it is not entirely clear which BCL-2 members are indispensable for CML stem cell survival. ABT-263, a potent BCL-2/BCL-X L inhibitor, has entered clinical trials for hematological malignancies. Although it has shown effectiveness, it causes pronounced thrombocytopenia, resulting from the depletion of BCL-X L -dependent platelets (25) . Thus, for the future development of this targeting concept, it is critical to determine whether inhibition of BCL-2 alone is sufficient to sensitize CML stem cells to TKIs.
ABT-199/GDC-0199 (venetoclax) is a potent and highly selective BCL-2 inhibitor with strong antitumor activity (26, 27) . Preclinical studies demonstrated that ABT-199 has activity against various hematological malignancies (28) (29) (30) (31) (32) . was recently approved by the U.S. Food and Drug Administration for chronic lymphocytic leukemia and has entered clinical testing for acute myeloid leukemia (AML), lymphoma, and multiple myeloma. A recent study showed that ABT-199 enhanced imatinib-induced CML progenitor cell death in vitro (33) . However, the effect of ABT-199 alone and in combination with TKIs on CML stem cells in vivo and stem/progenitor cells from patients with TKI-resistant BC has not been investigated.
Using CyTOF mass cytometry, a BCR-ABL transgenic murine model, and cells from patients with BC, we determined the role of BCL-2 in CML and the effect of its inhibition by ABT-199 alone and in combination with TKIs. We demonstrate the critical role of BCL-2 in CML cells and stem/progenitor cells and show that selective inhibition of BCL-2, aided by TKI-mediated BCL-X L /MCL-1 inhibition, has the potential to cure CML by eliminating CML stem cells.
RESULTS
Targeting of BCL-2 and BCR-ABL exerts potent antileukemic activity in BCR-ABL transgenic mice To assess the antileukemic activity of ABT-199 and TKI combinations in CML, we used an inducible transgenic CML mouse model (Scl-tTa-BCR-ABL) in an FVB/N background as previously described (34) . We withdrew tetracycline (Tet-off), and the mice developed a myeloproliferative disease as evidenced by increased white blood cell (WBC) and neutrophil counts and enlarged spleens ( fig. S1 ), reminiscent of human CML as previously described for this model. We collected bone marrow (BM) cells from these mice (Tet-off, n = 5; Tet-on, n = 4) and quantified Bcr-Abl, Bcl-X L , Mcl-1, and Bcl-2 as well as Bax, Bim, and Bid mRNA. Induction of Bcr-Abl expression was associated with markedly increased expression of Bcl-X L (Tet-off/Tet-on = 7.6-fold) and Mcl-1 (6.0-fold), and increased Bcl-2 expression (2.4-fold) (Fig. 1A) , consistent with previous reports for the regulation of antiapoptotic BCL-2 proteins by BCR-ABL (19, 20) . Induction was also observed to a lesser degree for proapoptotic BCL-2 proteins ( fig. S2A ).
To determine whether this transcriptional regulation translated into protein changes, we determined the expression of BCL-2 family proteins in the Tet-off (n = 6) and Tet-on (n = 5) mouse BM hematopoietic cells (CD45 + ) and also in the Lin
+ (LSK) cell population by CyTOF and SPADE analysis. CyTOF can simultaneously measure the expression of cell surface and intracellular proteins at a single-cell resolution and therefore determine protein expression in phenotypically defined rare cell populations. With SPADE, cell populations from all samples are clustered hierarchically according to the expression of surface markers and displayed in a single minimal spanning tree, where nodes can be annotated for further analysis. Figure 1B shows the LSK population (identified as a single node in the tree) and the expression of individual surface markers in the SPADE tree of mouse BM cell populations. As shown in Fig. 1C , we observed overall increases in BCL-2 and MCL-1, but not BCL-X L , protein expression in CD45 + cells in Tet-off compared to Tet-on mice, although the difference was not statistically significant. These increases in BCL-2 and MCL-1, as well as increased BCL-X L , were also detected in LSK cells. Only the BCL-2 protein expression was higher in LSK compared to CD45 + cells in Tet-off mice, and this difference was not observed in Tet-on mice. Although there were no major differences in proapoptotic proteins in CD45 + cells, BIM, BID, and BAX protein expression was increased in BM LSK cells from Tet-off compared to Tet-on mice. These data suggest a critical role for BCL-2 in the survival of CML bulk and stem/ progenitor cells and imply that CML stem cells may be sensitive to apoptosis induction by BCL-2 inhibition.
After demonstrating the effectiveness of ABT-199 and its combination with nilotinib in vitro ( fig. S2B ), we performed an in vivo study. We crossed Scl-tTa-BCR-ABL mice with transgenic green fluorescent protein (GFP)-expressing mice. Four weeks after Tet-off, BM cells from these mice were collected. GFP + cells were fluorescence-activated cell sorting (FACS)-sorted and injected into irradiated wild-type FVB/N mice (34) . Upon development of neutrophilic leukocytosis in the recipient mice, they were randomized into four groups (n = 14 to 16 per group), and treatment was initiated. At the end of the 23-day treatment period, three mice per group were sacrificed, and BM and spleen cells were collected ( Fig. 2A) . Treatment with ABT-199 significantly decreased the number of highly immature BM LSK cells (GFP + LSK) (P = 0.018; Fig. 2B ), whereas nilotinib had only modest effect. However, the activity of ABT-199 was enhanced by its combination with nilotinib (P = 0.009), and the combination was significantly more effective than either agent alone (P = 0.038 and P = 0.033 compared to ABT-199 and nilotinib, respectively). ) in the BM was lower in the three treatment groups as compared to the control group, the combination was more effective than ABT-199 or nilotinib alone (Fig. 2B) . The most pronounced effects were seen in LSK, CMP, and GMP cells, and less so in mature myeloid cells.
Both ABT-199 and the combination were highly active against spleen LSK cells, and an enhanced effect was discernible in mature myeloid cells (Fig. 2C) . We also analyzed BM and spleen GFP − LSK cells from treated mice because they may reflect the effects of treatments on normal stem/progenitor cells. Although the number of GFP − LSK cells decreased in the combination treatment group compared to controls, the effect was not significant ( fig. S3 ), suggesting selectivity of the treatment of CML cells.
At 8 weeks after cessation of treatment, we still observed strong antileukemic activity, which consisted of fewer total and leukemic WBCs and neutrophils in peripheral blood (PB) of all treatment groups relative to controls (Fig. 3A, top) . However, at 12 weeks, the mice treated with nilotinib alone showed reemergence of total and GFP + leukemia cells, resembling clinical disease relapse after TKI cessation. Mice treated with ABT-199 alone or in combination with nilotinib still demonstrated a reduction of leukemic WBCs and neutrophils (Fig. 3A, bottom) , indicating a persistent antileukemic activity.
The explanation for the similar leukemia burden observed in controls at 8 and 12 weeks was likely that mice with higher leukemia burden had died before the earlier time point. The nilotinib-treated mice (median survival, 70 days) tended to live longer than controls (median survival, 34.5 days) after discontinuation of therapy (Fig. 3B ), but the difference did not reach statistical significance (P = 0.2146). The median survival after ABT-199 treatment was 115 days, which was significantly longer than controls (P = 0.0079). This survival benefit was even more pronounced for the combination therapy group (median survival, 168 days; P = 0.0002; Fig. 3B ).
Inhibition of BCL-2 and BCR-ABL targets CML stem cells in BCR-ABL transgenic mice In a separate experiment, leukemic WBCs and neutrophils in each group were reduced to the same degree as in the first study at the end of the 23-day treatment period ( with cells from the ABT-199/nilotinib cotreatment group than in any other group. Figure 4B shows the percentages of GFP + PB cells in each group (left) and in individual mice (right) after a secondary transplant at 0.25 × 10 6 BM cells per mouse. We defined nonengraftment as PB GFP positivity of less than 1%, which was considered background (equivalent to the amount seen in sham transplanted FVB mouse). Figure 4C shows the numbers of engrafted versus tested mice in all groups and the long-term leukemia stem cell (LT-HSC) frequency, which differed significantly between groups (P = 3.51 × 10
−5
). Nilotinib treatment alone did not affect engraftment or LT-HSC frequency (P = 0.78) compared to controls, in agreement with previously published data, suggesting that TKIs are inactive against CML stem cells (1-3). Treatment with ABT-199 decreased the number of engrafted mice and LT-HSC frequency compared to controls (P = 0.049). Moreover, the combination treatment significantly decreased secondary engraftment and LT-HSC frequency (P = 9.38 × 10 −6 compared to controls and P = 0.006 compared to the ABT-199-treated group). For every 22.4 LT-HSCs detected in mice transplanted with BM cells from untreated CML mice, 9.67, 20.03, and only 1.05 such cells were found in mice transplanted with BM cells obtained from animals treated with ABT-199, nilotinib, and their combination, respectively.
In addition, we obtained BM cells from mice that had received a secondary transplant with 0.25 × 10 6 BM cells from each treatment group and determined the percentage of GFP positivity and extent of Bcr-Abl expression using real-time RT-PCR. Mice with ≥3 log reduction in BM Bcr-Abl mRNA also had ≤1% BM GFP positivity, and mice transplanted with BM cells from combination-treated donors had only background levels of GFP + cells and negligible Bcr-Abl mRNA expression (Fig. 4D ).
BCL-2 and BCR-ABL inhibition induces apoptosis in bulk and stem/progenitor BC CML cells To determine the effects of combined inhibition of BCL-2 and BCR-ABL on BC CML, we treated cells from BC CML patients (n = 6) with ABT-199, nilotinib, or the combination. Some of the patient samples had T315I or other mutations of BCR-ABL, and all six had experienced treatment failures with one or more TKIs ( To better understand antiapoptotic BCL-2 protein expression and ABT-199 sensitivity in CML cells, we determined the median inhibitory concentration (IC 50 ) of ABT-199 and the expression of BCL-2, BCL-X L , and MCL-1 by immunoblot in these samples ( fig. S4) . Samples 1 and 6 had the lowest amounts of BCL-2 and the highest IC 50 . Sample 4a had the highest BCL-2, but also the highest BCL-X L and high MCL-1, which made it relatively resistant to ABT-199. These data support ABT-199 specificity for BCL-2 and establish MCL-1 and BCL-X L as resistance factors for ABT-199. The combination therapy had minimal activity against normal BM (n = 3) CD34 + cells (Fig.  5B) . Similar results were obtained when ABT-199 was combined with other TKIs (fig. S5A) .
We assessed protein and gene expression of BCL-2 family members in selected samples (Table 1, patients 2, 4a, and 5) . Overall, ABT-199 treatment did not markedly decrease BCL-2 protein, as we expected. Nilotinib treatment partially decreased BCR-ABL signaling, as measured by the amount of phosphorylated CRKL (p-CRKL), and reduced MCL-1, BCL-X L , or both, while having only a minimal effect on BCL-2 expression. The combination greatly decreased p-CRKL expression and enhanced the reduction of all three BCL-2 family proteins, particularly MCL-1, regardless of whether mutations in BCR-ABL were detected in these samples (patients 2 and 4a) or not (patient 5) (Fig. 5C) .
Real-time RT-PCR analysis demonstrated that nilotinib treatment decreased Bcl-X L and Mcl-1 mRNA expression, further confirming their transcriptional regulation by BCR-ABL. Mcl-1 and Bcl-X L mRNA expression was further reduced by the combination treatment, but Bcl-2 mRNA expression was less affected (Fig. 5C ). Although the individual agents and the combination did not show marked reduction in the mRNA of proapoptotic BCL-2 proteins, some decreases in BAX and BID proteins were observed, especially with the combination treatment ( fig. S5B ). However, BIM protein expression was largely unchanged, and the basal amount of BAX protein was high and was still detectable after treatment. This is likely sufficient for induction of apoptosis because the combination treatment greatly diminished MCL-1, partially decreased BCL-X L expression, and antagonized BCL-2 function.
To determine whether the synergy of nilotinib and ABT-199 treatment was caused, at least in part, by TKI-mediated BCL-X L /MCL-1 inhibition, we knocked down the expression of BCL-X L , MCL-1, or both in cells obtained from BC patients (Table 1 , patients 2, 3, and 4a) by specific siRNAs. Twenty-four hours later, the cells were treated with ABT-199 for additional 48 hours. A partial inhibition of BCL-X L and MCL-1 slightly increased the sensitivity of CML cells to (Fig.  5D) , suggesting that the cooperative inhibition of BCL-2 and BCL-X L / MCL-1 contributed to the observed synergy.
Targeting of BCL-2 and BCR-ABL induces apoptosis in quiescent CD34
+ BC CML cells To evaluate the effects of ABT-199 and TKI combinations on TKIinsensitive quiescent CML stem/progenitor cells, we labeled cells from BC CML patients with the cell division-tracking dye carboxyfluorescein succinimidyl ester (CFSE) and cocultured them with human BM-derived MSCs. Once proliferating and quiescent cells were distinguishable by flow cytometry, they were treated with ABT-199, TKIs, and combinations for 48 hours. Apoptosis was determined in proliferating (CD34 Figure 6A shows the flow cytometric profiles of one patient's cells before and after treatments (upper panel; patient 8) and of six patients after treatments (lower panel; patients 1 to 3, 4b, 7, and 8, Table 1 ). The combination was significantly more effective than either agent alone in inducing apoptosis in proliferating CD34 + cells from all six patients, and although it was less effective than in proliferating cells (P = 0.0255), it was also significantly more effective than either agent alone in quiescent CD34
+ cells. We previously demonstrated that MSCs in the BM microenvironment protect AML cells, in part, by inducing the expression of antiapoptotic proteins (35, 36) . Here, we found that coculture of BC CML cells with MSCs also increased the expression of antiapoptotic BCL-2, BCL-X L , and MCL-1 proteins. Figure 6B illustrates a representative result from one patient sample and quantitative results from five patient samples. These increases are unlikely due to MSC contamination because negligible amounts of MSCs were found in the collected leukemia cells (fig. S6A) , and we did not see similar changes in proapoptotic BCL-2 proteins ( fig.  S6B ). Cocultures with MSCs partially protected proliferating but not quiescent CD34 + cells from ABT-199/nilotinib-induced apoptosis (Fig. 6C ). The combination treatment was highly synergistic in inducing apoptosis in both proliferating (mean CI ± SD, 0.020 ± 0.015) and quiescent (mean CI ± SD, 0.011 ± 0.010) leukemia cells, even when these cells were cocultured with MSCs (mean CI ± SD, 0.006 ± 0.005 for proliferating and 0.018 ± 0.018 for quiescent cells) (Fig. 6C) 
DISCUSSION
Although TKIs have markedly improved long-term survival for CML patients, the vast majority of them have residual disease as determined by Bcr-Abl RT-PCR. Relapse occurs in >50% of these patients upon discontinuation of treatment, even in patients who achieved complete molecular responses. Thus, to control the disease, patients need to be treated with TKIs continuously. Consequently, the number of CML survivors on continuous treatment is ever increasing, and there will be more than 100,000 patients with CML in 2020 in the United States alone (37) . Long-term treatment with TKIs for these patients comes at a high cost, both in terms of side effects [see (38) for a review] and financially. Worldwide, most CML patients cannot afford the extraordinary expenses associated with TKI-based therapy. Furthermore, acquired BCR-ABL mutations that render TKIs ineffective can develop, and in patients progressing to BC, there are no meaningful responses to TKIs and survival is counted in weeks or months.
We and others identified BCL-2 as a key survival factor for myeloid leukemia cells (16, 17, 31) . Antiapoptotic BCL-2 proteins were reported to be regulated by BCR-ABL tyrosine kinase (19, 20) . However, their induction at the protein level, especially in stem/progenitor cells, has not been not well investigated. Although several studies (17, (21) (22) (23) have shown that BH3 mimetics synergize with TKIs to target CML cells and stem/progenitor cells, none has established a critical role of BCL-2 in CML stem cell survival.
We determined BCL-2 protein expression and examined whether selective BCL-2 inhibition could render CML cells, including stem cells, more sensitive to TKIs. To mimic human chronic-phase CML, we used a validated inducible transgenic CML mouse model (39, 40) . We observed higher Bcl-X L and Mcl-1 and, to a lesser degree, Bcl-2 mRNA expression in BM cells in Tet-off as compared to Tet-on BCR-ABL-transgenic mice, supporting the transcriptional regulation of these proteins by BCR-ABL. Aided by CyTOF, we found that BCL-2 was not only induced in CML cells but also differentially overexpressed in LSK versus bulk CML cells at the protein level, suggesting its critical role in CML stem cells. Treatment of the CML mice with ABT-199 decreased leukemia burden and LSK leukemic cells in the BM, which greatly prolonged the survival of CML mice. It also decreased engraftment and leukemia LT-HSC frequency in mice upon secondary transplantation, supporting a critical role of BCL-2 in CML cell/stem cell survival. Nilotinib showed stronger antileukemic activity in circulating blood than in the BM. Although nilotinib tended to decrease the numbers of various CML cell populations, it failed to significantly affect leukemic LSK cells. Like ABT-199, nilotinib was highly effective in controlling leukemia burden in PB even at 8 weeks after treatment discontinuation. However, at 12 weeks, in contrast to ABT-199, the antileukemic effect of nilotinib was lost, which mirrored the relapses observed in CML patients upon cessation of TKI therapy. When ABT-199 and TKIs were combined, the enhanced antileukemic activity was reflected in reduced leukemia burden and increased survival of CML mice after only 23 days of treatment. The combination was highly effective in preventing secondary engraftment and reducing leukemia LT-HSC frequency, suggesting the eradication of leukemia stem cells and potential of curing CML with an optimized treatment schedule.
It has been reported that cellular BCL-2 protein expression correlates with cell sensitivity to . The amount of antiapoptotic BCL-2 proteins increases in CML patients as they progress to BC, as determined by reverse-phase protein arrays (18) and quantitative RT-PCR (17) . Samples that were examined in vitro were obtained from TKI-resistant patients with BC CML, and we showed that treatment with nanomolar concentrations of ABT-199 induced apoptosis in these cells. These concentrations of ABT-199 have been achieved systemically in clinical trials in chronic lymphocytic leukemia and AML (41) .
Apoptosis was synergistically enhanced by combining ABT-199 with TKIs in BC CML, likely because of the partial inhibition of MCL-1 and, to a lesser degree, BCL-X L by TKIs. The fact that exposure to Mcl-1/Bcl-X L siRNAs sensitized cells to ABT-199, even with insufficient knockdown of MCL-1/BCL-X L in patient samples, supports this notion. We found that combined inhibition of BCL-2 and BCR-ABL cooperatively targeted antiapoptotic BCL-2 proteins. Although we cannot exclude the possibility that some samples may consist of more than one clone and that some of the clones were sensitive to one or more TKIs, clinical PCR monitoring showed that patient 4 had a T315I mutation in 100% of the PCR product. Nilotinib had minimal effect on p-CRKL and no effect on MCL-1 and BCL-X L in this patient. When nilotinib was combined with ABT-199, p-CRKL and MCL-1 were greatly reduced and BCL-X L also decreased.
We and others have reported that TKI activity can be enhanced by multiple agents other than ABT-199, even in TKI-resistant cells (24, 34, 42) . For ABT-199 and TKI combinations, in addition to the proposed mechanisms, we cannot rule out other mechanisms, particularly because we observed further decreases of not only p-CRKL but also total CRKL in all samples with the combination treatment. Cellular functions are dynamically regulated by multiple interacting pathways to determine their outcomes. Combination therapies can modify protein dynamics and change cell fates, providing new therapeutic opportunities (43) , likely also the case for combinations of TKIs and ABT-199.
Collectively, our results demonstrate that combined blockade of prosurvival BCL-2 and an oncogenic tyrosine kinase has the potential of curing CML and improving outcomes in patients with BC, and as such, it warrants clinical testing. This combination strategy may also apply to other malignancies that depend on kinase signaling for progression and maintenance.
MATERIALS AND METHODS

Study design
This study was designed to test the hypothesis that inhibition of BCL-2 in combination with TKIs that affect MCL-1/BCL-X L inhibition has the potential to eradicate CML stem cells and BC CML cells. We demonstrated in chronic-phase CML, using an established inducible transgenic mouse model, that the combination eliminates leukemic LSK cells, prolongs survival, and decreases leukemia stem cell frequency in secondary transplant experiments. In BC CML, using TKI-resistant samples from patients, we showed that the combination is effective in killing bulk, CD34 In vivo study Mouse care and experiments were performed in accordance with protocols approved by the Animal Care and Use Committee of the University of Texas MD Anderson Cancer Center. All mice are on an FVB/N background. Inducible transgenic Scl-tTa-BCR-ABL/GFP mice were generated as described previously (34, 39, 40) . Four weeks after Tet-off induction of Bcr-Abl expression in the mice, GFP-expressing cells in mouse BM were sorted by flow cytometry and transplanted by tail vein injection (0.6 × 10 6 cells per mouse) into wild-type FVB/N recipient mice (Jackson Laboratory) irradiated at 900 cGy. After they developed neutrophilic leukocytosis, the mice were randomized and given [100 mg/kg; vehicle: 60% Phosal 50 PG, 30% PEG400 (polyethylene glycol, molecular weight 400), and 10% ethanol] (27, 31) , nilotinib (50 mg/ kg; vehicle: 10% N-methyl-2-pyrrolidone and 90% PEG300) (44, 45) Cells, cell culture, and cell treatment Samples were acquired from BC CML patients and normal controls after informed consent following the University of Texas MD Anderson Cancer Center Institutional Review Board-approved protocol. The patients' characteristics are listed in Table 1 . Mononuclear cells from these samples and BM cells from Tet-off (3 to 4 weeks) and Tet-on transgenic Scl-tTa-BCR-ABL mice were cultured in a minimum essential medium supplemented with 10% heat-inactivated fetal calf serum, 2 mM L-glutamine, penicillin (100 U/ml), and streptomycin (100 mg/ml) and treated with ABT-199, TKIs, or their combinations. Doxycycline (1 mg/ml) was included in the medium for cells from Tet-on mice.
Identification and treatment of proliferating and quiescent CML cells Proliferating and quiescent cells were identified by staining mononuclear cells obtained from BC CML patients with CFSE and coculturing them with human BM-derived MSCs as described previously (21, 46) . Cell proliferation was monitored using flow cytometric measurement of cellular CFSE intensity, which halved with cell division, and compared with that of colcemid-treated (100 ng/ml) cells. Once proliferating and quiescent cells became distinguishable (coculture days and % quiescent CD34
+ cells for each sample are shown in Table 1 ), cells were treated with ABT-199, TKIs, and the combinations with or without MSC coculture. MSCs were isolated from BM samples from healthy subjects as described previously (47) . Quiescent cells are defined as those in a region of CFSE fluorescence of colcemid-treated cells (CFSE bright ) and proliferating cells as those with fluorescence intensity less than the control cells (CFSE dim ). 
Apoptosis assay
Immunoblot analysis
Proteins were quantified by immunoblot analysis as described previously (21, 24) . For coculture experiments, leukemia cells were collected by combining cells in the supernatant and after two washes with PBS. Antibodies against p-CRKL, BID, and BCL-X L were purchased from Cell Signaling Technology, MCL-1 from Santa Cruz Biotechnology Inc., BIM and CRKL from Abcam, BAX from Sigma, and BCL-2 from Dako. Signals were detected using an Odyssey infrared imaging system and quantitated using the Odyssey software program (version 3.0; LI-COR Biotechnology). b-Actin (Sigma) was used as a loading control.
Real-time RT-PCR
Cell pellets were lysed in TRIzol solution (Thermo Fisher Scientific), and RNA was isolated as described previously (48 method, in which DC t is the mean cycle threshold (C t ) of the transcript of interest minus the mean C t of Abl transcript.
Protein determination by CyTOF mass cytometry BM cells collected from Tet-on (n = 5) and Tet-off (n = 6) mice were stained with a panel of metal-tagged antibodies (table S2) against cell surface and BCL-2 family proteins and subjected to CyTOF analysis as previously described (49) . Flow cytometry standard (FCS) files from individual samples were normalized against EQ beads loaded with each sample, using v.2 beads passport in CyTOF software (Fluidigm). Viable (cisplatin-low) single cells were gated with FlowJo software (v10.1r5; FlowJo LLC) and exported as FCS data for subsequent analysis in SPADE (v3.0; http://pengqiu.gatech.edu/software/SPADE/). A SPADE tree was generated using all surface markers (table S2) . The LSK node(s) was identified by negative expression of lineage markers (table S2) and positive expressions of Sca-1 and cKit. ArcSinh-transformed counts for each marker were then exported and visualized with heat maps to show differences in bulk and LSK populations and between Tet-off and Tet-on mice.
Knockdown of protein expression
To transiently knock down the expression of BCL-X L , MCL-1, or both, PB cells from CML patient samples (2, 3, and 4a, Table 1 ) were transfected with siRNAs for Bcl-X L , Mcl-1, or both (ON-TARGETplus SMARTpool; Thermo Scientific Dharmacon) via electroporation using an Amaxa apparatus (Amaxa Biosystems) following the manufacturer's instructions.
Statistical analyses
The results were expressed as means ± SEM. Statistical significance was set at P < 0.05 using the two-sided Student's t test. The CI, determined using the Chou-Talalay method (50) , was expressed as the mean of CI values obtained at the effective doses in 50, 75, and 90% of the mean ± SD of the population exposed to the agents: CI < 1 (synergistic), CI = 1 (additive), and CI > 1 (antagonistic). Mouse survival data were analyzed using the log-rank test. LT-HSC frequency was calculated using the Extreme Limiting Dilution Analysis software program (http://bioinf.wehi. edu.au/software/elda/) (51) . Original data are shown in tables S3 to S13.
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